–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life Sept. 01, 2026 -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biot

Aug. 18, 2026 -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced today that new data from a multi-institutional feasibility clinical trial across 15 institutions nationwide presented by Clark Chen, M.D., Ph.D., professor and director of the Brain Tumor Program at Brown University Health, suggest that a novel radiation therapy device may help improve outcomes for patients newly diagnosed with glioblastoma, one of th

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2. Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile. TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. July 22, 2026 -- Teli

July 10, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), today announced that the Journal of Autoimmunity has published results from a clinical study evaluating orelabrutinib, a BTK (Bruton’s tyrosine kinase) inhibitor, in patients with systemic lupus erythematosus (SLE). The study confirmed for the first time that orelabrutinib is well-tolerated and efficacious in patients with SLE, marking orelabrutinib as the first BTK inhibitor to show clinical efficacy in treating SLE. Professor Ru Li

Partillion Bioscience highlights new research underscoring Nanovial technology as an enabling platform for scalable functional cell-cell interaction datasets. July 2, 2026 -- A new Nature Biotechnology perspective article, authored by researchers from UCLA and collaborating institutions, is bringing renewed attention to cell-cell interaction data as an important missing layer for understanding complex biology and advancing foundation models in biology. Cell-cell interaction data captures how c

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities. Revolution Medicines’ second RAS inhibitor elicited encouraging response rates in a Phase 1/2 study of pancreatic cancer, further strengthening the biotech’s leadership position in this disease. Revolution’s lead asset, daraxonrasib, made waves in April when the company announced that it doubled overall survival versus chemot

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC's multi-target approach in Alzheimer's disease June 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive

A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.Researchers in Spain and Switzerland have identified an experimental molecule that may help restore the brain's natural defenses against Alzheimer's disease. The compound, known as OLE, appears to "reprogram" microglia, the brain's immune cells, allowing them to

Scientists at Baylor College of Medicine may have uncovered a promising new way to combat Alzheimer’s and Parkinson’s disease. Instead of trying to stop Tau and alpha-synuclein proteins from gathering into tiny droplets inside brain cells, the researchers found that tubulin—the protein that builds the cell’s internal transport network—can redirect these proteins away from forming toxic clumps and toward healthy, productive work.Scientists at Baylor College of Medicine have identified a potential

The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSP